The major evolutionary routes to drug resistance in Salmonella Typhi are associated with fitness benefits, not fitness costs, implying that prudent antimicrobial use will have no effect as a public health intervention in controlling typhoid fever.
A fluoroquinolone resistant variant of Salmonella Typhi has emerged that is likely to be widespread in the Indian subcontinent; therefore fluoroquinolones should not be recommended for empirical typhoid fever therapy in this setting.
Mass spectrometry on plasma from patients with typhoid fever and other febrile disease identified and validated 24 metabolites that can distinguish typhoid from other febrile diseases, providing a new approach for typhoid diagnostics.
Biochemical analyses and the crystal structure of TtsA reveal fundamental insight into the mechanisms by which this muramidase recognizes its peptidoglycan substrate to facilitate typhoid toxin secretion.
Acquisition of antibiotic resistance plasmids induces collateral sensitivity to clinically relevant antibiotics in Escherichia coli, paving the way for targeted 'anti-plasmid' therapies able to preferentially eliminate plasmid-carrying bacteria.